Navigation Links
Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
Date:10/9/2008

Patent will protect next generation of Qoustic Wound Therapy System(R)

MINNEAPOLIS, Oct. 9 /PRNewswire/ -- Arobella Medical, LLC, a leader in advanced ultrasonic wound care devices, today announced that its Co-founder, President and CEO Eliaz Babaev, Ph.D., has been issued a U.S. patent that covers technology employed in the next generation of the company's Qoustic Wound Therapy System(R).

The Qoustic Wound Therapy System, which offers a safe, cost-effective alternative to painful sharps debridement and other surgical modalities, is emerging as the gold standard for wound care. Light guidance contact produces a dual delivery of low-frequency ultrasound energy directly on the wound bed. This process gently, thoroughly and efficiently debrides the wound and provides stable cavitation to remove dead or diseased tissue, harmful bacteria and biofilm. Ultrasonic treatment also expedites healing by preserving healthy tissue and protecting granulation tissue, improving circulation through vasodilation and angiogenesis, and preparing the wound bed for more effective use of downstream therapies such as grafts and flaps.

"This patent, which is the first of many that are currently pending, will help protect the next generation of this product that is poised to become the latest breakthrough in wound care today," said Babaev.

The first generation of the Qoustic Wound Therapy System family was launched in February 2008.

About Arobella Medical, LLC

Arobella Medical, LLC is a Minneapolis-based medical device company specializing in low-frequency ultrasound for wound care and other wound management therapies. Arobella Medical is positioned to become a leader in advanced ultrasound wound care technologies and devices. Arobella Medical Co-founder and CEO Eliaz Babaev has more than 40 years of experience developing, designing and commercializing medical devices that use ultrasound, with over 40 patents worldwide. He holds a Ph.D. degree from the Moscow Bauman School, a Doctor of Science degree from the Latvia Academy of Science, and a Doctor of Science degree from the Russian State Supreme Certification Committee, all in biomedical ultrasound. For more information, go to http://www.arobella.com


'/>"/>
SOURCE Arobella Medical, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
5. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
6. BioMS Medical announces its intention to renew a normal course issuer bid
7. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Globus Medical Announces Record 2nd Quarter 2007 Results
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):